Shurui Robotics, one of China’s surgical robot “four dragons”, has had its STAR Market IPO application accepted. This is the company’s second attempt at a public listing after a 2023 effort was abandoned.
The company is using the fifth STAR Market listing standard, which requires a minimum expected valuation of 4 billion yuan but does not mandate revenue or profit thresholds. Shurui plans to raise 700 million yuan: 280 million for product R&D, 210 million for a global marketing network, and 210 million for working capital.
The technology
Founded by Shanghai Jiao Tong University professor Xu Kai, a Tsinghua master’s and Columbia PhD graduate with more than 20 years in surgical robotics, Shurui has achieved full-chain mastery of single-port laparoscopic surgical robot technology.
Its core product, the SR-ENS-600, uses a snake-like surgical instrument powered by superelastic nitinol alloy, controlled by a multi-elastomer nonlinear large-deformation algorithm. It is China’s first and the world’s second approved single-port surgical robot. It is also the first Chinese surgical robot approved for the full EU population, and the only single-port robot globally with CE certification for paediatric surgery.
Clinical traction
Shurui’s robot has completed more than 3,500 clinical surgeries across urology, gynaecology, general surgery, thoracic surgery and paediatric surgery. It has secured commercial projects at 19 top-tier Chinese hospitals and completed nearly 40 global first-in-procedure surgeries.
Internationally, the system has won regulatory approval in the EU, Hong Kong and Malaysia. In H1 2026, it won a tender at a major Spanish public hospital at a direct sales price of EUR 2.42 million, achieved commercial installation at Munich’s largest public hospital on a per-use basis, and gained procurement qualification from France’s largest public healthcare purchasing alliance.
Financials
Revenue grew from 449,000 yuan in 2023 to 18.63 million yuan in 2024 to 81.31 million yuan in 2025, year-on-year growth of 4,051 per cent then 337 per cent. Net losses narrowed from 191 million yuan to 195 million yuan to 132 million yuan over the same period, with the loss rate dropping from 42,513 per cent to 1,049 per cent to 162 per cent.
The company has filed 732 patents, with 471 granted. Investors include State Investment and Merchants Capital, Shunshi Capital, Medtronic, Zhengxingu Capital, Hefei Industry Investment, and Shanghai Biomedical Fund.
Editor’s note: This is an adapted translation of the original OFweek report. It has been trimmed and restructured for readability for an international business audience.